Inducible Clindamycin Resistance and Molecular Epidemiologic Trends of Pediatric Community-acquired Methicillin-resistant Staphylococcus Aureus in Dallas, Texas
Overview
Authors
Affiliations
Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infection occurs commonly in children. Clindamycin resistance may be inducible or constitutive, and the rates of inducible resistance in CA-MRSA that could produce clindamycin treatment failures vary worldwide. The double-disk test was performed in 197 erythromycin-resistant and clindamycin-susceptible CA-MRSA strains from children in Dallas, Texas, from 1999 to 2002 to determine inducible clindamycin resistance. Resistance mechanisms were studied by PCR; epidemiologic trends were studied by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Inducible resistance was demonstrated in 28 (93%+/-6%) of 30 tested isolates in 1999, 21 (64%, +/-11%) of 33 in 2000, 12 (23%+/-7%) of 52 in 2001, and 6 (7%+/-3%) of 82 in 2002. All noninducible strains had the msr(A) gene. Among inducible resistant strains, 31 had erm(B), 24 had erm(C), and 12 had erm(A) genes. Two distinct pulsed types were the most prevalent; one of them was the most common pulsed type in 1999, whereas in 2002 a different pulsed type was prevalent. MLST analyses determined that ST-8 was the most common type, with 76%+/-5% found in 2002. All but one of these clindamycin-susceptible, erythromycin-resistant ST-8 strains showed no induction of clindamycin resistance. We conclude that, among erythromycin-resistant, clindamycin-susceptible CA-MRSA strains isolated from children in Dallas, inducible methylase resistance became less common from 1999 to 2002 (P<0.001). The phenotype of strains was associated with their sequence type. Our results demonstrate a clonal shift in CA-MRSA in Dallas children from 1999 to 2002.
Macias A, Stimes G, Kaplan S, Vallejo J, Hulten K, McNeil J Antibiotics (Basel). 2025; 14(1.
PMID: 39858392 PMC: 11763315. DOI: 10.3390/antibiotics14010107.
Chopjitt P, Tangthong P, Kongkaem J, Wonkyai P, Charoenwattanamaneechai A, Khankhum S Biomol Biomed. 2024; 25(2):461-471.
PMID: 39388710 PMC: 11734814. DOI: 10.17305/bb.2024.11116.
Kansaen R, Boueroy P, Hatrongjit R, Kamjumphol W, Kerdsin A, Chopjitt P Antibiotics (Basel). 2023; 12(8).
PMID: 37627707 PMC: 10451473. DOI: 10.3390/antibiotics12081287.
Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice.
Armengol Alvarez L, Van De Sijpe G, Desmet S, Metsemakers W, Spriet I, Allegaert K Antibiotics (Basel). 2022; 11(5).
PMID: 35625345 PMC: 9137603. DOI: 10.3390/antibiotics11050701.
Donadu M, Ferrari M, Mazzarello V, Zanetti S, Kushkevych I, Rittmann S Pathogens. 2022; 11(4).
PMID: 35456146 PMC: 9031815. DOI: 10.3390/pathogens11040471.